|
|
|
|
|
Andrew J. White, M.D.
|
|
Assistant Professor of Pediatrics
Director, Pediatric Residency Program
Rheumatology
Dr. Andrew White grew up in San Antonio, Texas, and is a tropical fish hobbyist, (some would say nut) as well as an avid wind-surfer.
He received his undergraduate education at Brandeis University in Boston, spent 3 years at the University of Chicago working on derivatives of cubane in pursuit of a PhD in organic chemistry, but then decided to earn his medical degree from the University of Texas Southwestern Medical School. Dr. White was an intern, resident and fellow at the St. Louis Children's Hospital at the Washington University School of Medicine in St. Louis. He is a member of the American Board of Pediatrics. Dr. White is Board certified in Pediatrics and Pediatric Rheumatology by the American Academy of Pediatrics.
Dr. White is the program director of the Residency Program in Pediatrics at St. Louis Children's Hospital and also the Director of Rheumatology Services at the Shriner's Hospital.
Dr. White's current research focuses on the clinical efficacy of novel pharmacotherapeutics in the treatment of juvenile rheumatoid arthritis, as well as investigations of gene expression arrays in familial autoimmune diseases. He also is the Co-Director of the Osler Weber Rendu (aka Hereditary Hemorrhagic Telangiectasia) Center of Excellence at Washington University.
|
Andrew J. White, M.D.
|
|
Assistant Professor of Pediatrics
Director, Pediatric Residency Program
Rheumatology
Dr. Andrew White grew up in San Antonio, Texas, and is a tropical fish hobbyist, (some would say nut) as well as an avid wind-surfer.
He received his undergraduate education at Brandeis University in Boston, spent 3 years at the University of Chicago working on derivatives of cubane in pursuit of a PhD in organic chemistry, but then decided to earn his medical degree from the University of Texas Southwestern Medical School. Dr. White was an intern, resident and fellow at the St. Louis Children's Hospital at the Washington University School of Medicine in St. Louis. He is a member of the American Board of Pediatrics. Dr. White is Board certified in Pediatrics and Pediatric Rheumatology by the American Academy of Pediatrics.
Dr. White is the program director of the Residency Program in Pediatrics at St. Louis Children's Hospital and also the Director of Rheumatology Services at the Shriner's Hospital.
Dr. White's current research focuses on the clinical efficacy of novel pharmacotherapeutics in the treatment of juvenile rheumatoid arthritis, as well as investigations of gene expression arrays in familial autoimmune diseases. He also is the Co-Director of the Osler Weber Rendu (aka Hereditary Hemorrhagic Telangiectasia) Center of Excellence at Washington University.
|
|
|
|
|
|
|
1986 BA, Brandeis University
1989 MSc, University of Chicago
1994 MD, University of Texas Southwestern Medical School, Dallas
1986 BA, Brandeis University
1989 MSc, University of Chicago
1994 MD, University of Texas Southwestern Medical School, Dallas
|
|
|
|
|
|
1994 - 1997 Intern and Resident, St. Louis Children's Hospital
1997 - 2000 Fellow, Pediatric Immunology and Rheumatology, Washington University School of Medicine, St. Louis, MO
1994 - 1997 Intern and Resident, St. Louis Children's Hospital
1997 - 2000 Fellow, Pediatric Immunology and Rheumatology, Washington University School of Medicine, St. Louis, MO
|
|
|
|
|
|
1997 - 2004 MO 106516
1999 - 2006 American Board of Pediatrics; General Pediatrics
2000 - 2007 American Board of Pediatrics; Rheumatology, renewed 2007
2006 - 2007 American Board of Pediatrics; General Pediatrics, renewed 2007
1997 - 2004 MO 106516
1999 - 2006 American Board of Pediatrics; General Pediatrics
2000 - 2007 American Board of Pediatrics; Rheumatology, renewed 2007
2006 - 2007 American Board of Pediatrics; General Pediatrics, renewed 2007
|
|
|
|
|
|
2003 - 2004 Clinical Teacher of the Year, Washington University School of Medicine
2006 - 2007 Clinical Teacher of the Year, Washington University School of Medicine
2003 - 2004 Clinical Teacher of the Year, Washington University School of Medicine
2006 - 2007 Clinical Teacher of the Year, Washington University School of Medicine
|
|
|
|
|
|
Peer Reviewed:
1. Eaton PE, White AJ. The mechanism of olefin-to-carbene rearrangement for 9-phenyl-1(9)-homocubene. J Org Chem 1990; 55(4):1321.
2. Verbsky JW, White AJ. Effective Use of the Recombinant IL-1 Receptor Antagonist Anakinra in Therapy Resistant Systemic Onset Juvenile Rheumatoid Arthritis. J Rheumatol 2004; 31:2071-2075.
3. Thatayatikom A, White AJ. Clinical Allergy-Immunology Rounds, “Swollen uvula in an 18-year-old male with hypogammaglobulinemia.” Ann Allergy Asthma Immunol 2004; 93:417-424.
4. White AJ, Raman V, Blaeser F. Ho N, Chatila T. Protection against T cell Apoptosis by a Ca2+-insensitive mutant of the transcription factor MEF2D, (in preparation).
5. Thatayatikom A, White AJ. “Rituximab: A Promising Therapy in Systemic Lupus Erythematosus.” Autoimmunity Review Journal. 2006 Jan 5(1): 18-24.
6. Thatayaikom A, Thatayaikom S, White A. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol. 2005 Sept 95(3): 293-300.
7. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, Ilowite N, Hom C, Cawkwell G, White A, Rivas-Chacon R, Kimura Y, Ray L, Ramsey-Goldman R. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatrics. 2006 Feb 148(2): 247-53.
8. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: A report of four pediatric patients. Arthritis and Rheumatism. Sep 56(9):3107-11, 2007.
Books:
1. Pediatrics Survival Guide, The Washington Manual Survival Guide Series, Ed. Arbelaez AM and Garmany TH, Lippincott Williams & Wilkins, 2004, White AJ, Faculty Advisor.
Peer Reviewed:
1. Eaton PE, White AJ. The mechanism of olefin-to-carbene rearrangement for 9-phenyl-1(9)-homocubene. J Org Chem 1990; 55(4):1321.
2. Verbsky JW, White AJ. Effective Use of the Recombinant IL-1 Receptor Antagonist Anakinra in Therapy Resistant Systemic Onset Juvenile Rheumatoid Arthritis. J Rheumatol 2004; 31:2071-2075.
3. Thatayatikom A, White AJ. Clinical Allergy-Immunology Rounds, “Swollen uvula in an 18-year-old male with hypogammaglobulinemia.” Ann Allergy Asthma Immunol 2004; 93:417-424.
4. White AJ, Raman V, Blaeser F. Ho N, Chatila T. Protection against T cell Apoptosis by a Ca2+-insensitive mutant of the transcription factor MEF2D, (in preparation).
5. Thatayatikom A, White AJ. “Rituximab: A Promising Therapy in Systemic Lupus Erythematosus.” Autoimmunity Review Journal. 2006 Jan 5(1): 18-24.
6. Thatayaikom A, Thatayaikom S, White A. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Ann Allergy Asthma Immunol. 2005 Sept 95(3): 293-300.
7. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, Ilowite N, Hom C, Cawkwell G, White A, Rivas-Chacon R, Kimura Y, Ray L, Ramsey-Goldman R. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatrics. 2006 Feb 148(2): 247-53.
8. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: A report of four pediatric patients. Arthritis and Rheumatism. Sep 56(9):3107-11, 2007.
Books:
1. Pediatrics Survival Guide, The Washington Manual Survival Guide Series, Ed. Arbelaez AM and Garmany TH, Lippincott Williams & Wilkins, 2004, White AJ, Faculty Advisor.
|
|
|